DCGI approves DRDO-developed anti-Covid oral drug, could reduce supplemental oxygen dependence
With the 35 years old Rs 400 crore medical syringes brand Dispovan and the Defence Research Development Organisation's (DRDO) Dipcovan - coronavirus antibody detection kit - sounding similar, Hindustan Syringes & Medical Devices Ltd will request the defence lab to have a different brand name, said a top company official.
"We will politely request DRDO to go in for a different name for the coronavirus antibody detection kit as the brand name Dipcovan sounds very similar to that of our 35 years old medical syringe brand Dispovan," Rajiv Nath, Managing Director, Hindustan Syringes, told IANS.
Dispovan owner to urge DRDO for new name of Covid anti-body kit prokerala.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prokerala.com Daily Mail and Mail on Sunday newspapers.
DRDO's Indigenous COVID-19 Antibody Detection Kit to Hit the Markets Soon
DIPCOVAN kit will be very useful for understanding COVID‐19 epidemiology and assessing an individual's previous SARS‐CoV‐2 exposure
| 21 May 2021 3:36 PM GMT
New Delhi: Defence Institute of Physiology and Allied Sciences (DIPAS), a laboratory of Defence Research and Development Organisation (DRDO), has developed DIPCOVAN kit, an indigenous COVID-19 antibody detection-based kit, to be sold across India from June first week.
It is expected to be available at about Rs 75 per test. The kit will be very useful for understanding COVID‐19 epidemiology and assessing an individual's previous SARS‐CoV‐2 exposure.
Reports said that it can detect both spike and nucleocapsid (S&N) proteins of SARS-CoV-2 virus with a high sensitivity of 97 per cent and specificity of 99 per cent.
DRDO’s Covid antibody testing kit
May 21, 2021
The kit has a high sensitivity of 97%, specificity of 99%
Conducting sero surveillance studies for Covid-19 will now be cheaper and easier with Indian defence scientists developing an indigenous antibody detection kit with high sensitivity and specificity.
Validation The kit, developed by researchers at the Defence Institute of Physiology and Allied Sciences (DIPAS), a laboratory of Defence Research and Development Organisation, has already undergone extensive validation using more than 1,000 patient samples at various Covid-designated hospitals in Delhi. It has already been validated by the Indian Council of Medical Research and has received regulatory approval of the Drugs Controller General of India, said a statement on Friday.
DRDO develops antibody test kit DIPCOVAN for early detection of COVID-19
DRDO develops antibody test kit DIPCOVAN for early detection of COVID-19
ANI / Updated: May 21, 2021, 17:05 IST
DRDO) has developed an
COVID.
DIPCOVAN, the DIPAS-VDx COVID 19 IgG Antibody Microwell ELISA for sero-surveillance has been developed by the Defence Institute of Physiology and Allied Sciences (DIPAS) in association with Delhi-based firm Vanguard Diagnostics Pvt Ltd.
According to DRDO, the kit can detect spike as well as nucleocapsid (S and N) proteins of SARS-CoV-2 virus with a high sensitivity of 97 per cent and specificity of 99 per cent. It was developed indigenously by scientists, followed by extensive validation on over 1000 patient samples at various COVID hospitals in Delhi.
The DIPCOVAN kit can detect both spikes as well as nucleocapsid (S&N) proteins of the SARS-CoV-2 virus with a high sensitivity of 97 per cent and specificity of 99 per cent
The Defence Research and Development Organisation (DRDO) has developed an antibody detection kit known as Dipcovan, which is expected to be available at Rs 75 per test in the market from June first week onwards.The kit has been developed by the ...
After 2-DG drug, DRDO develops Covid antibody detection kit
DRDO said three batches of the product were validated for the last one year. The antibody detection kit was approved by the Indian Council of Medical Research (ICMR) in April 2021.
Share Via Email
| A+A A-
The kit is believed to be very useful for understanding COVID-19 epidemiology and assessing an individual's previous SARS-CoV-2 exposure. (Photo | @DRDO_India) By Express News Service
NEW DELHI: The Defence Research and Development Organisation (DRDO) has developed an antibody test kit for the early screening of COVID.
DIPCOVAN, the DIPAS-VDx COVID 19 IgG Antibody Microwell ELISA for sero-surveillance has been developed by the Defence Institute of Physiology and Allied Sciences (DIPAS) in association with Delhi-based firm Vanguard Diagnostics Pvt Ltd.
Coronavirus | DRDO develops antibody detection kit
Updated:
Updated:
Commercial launch of product in June first week
Share Article
Commercial launch of product in June first week
The Defence Research and Development Organisation (DRDO) on Friday said it had, in collaboration with a company, developed an antibody detection kit for spotting SARS-CoV-2 virus with a high sensitivity of 97% and specificity of 99%.
“The DIPCOVAN kit was developed indigenously by the scientists, followed by extensive validation on more than 1,000 patient samples at various COVID designated hospitals in Delhi. Three batches of the product were validated during last one year. The antibody detection kit is approved by Indian Council of Medical Research (ICMR) in April 2021,” it said in a statement.
DRDO Scientists Develop Indigenous COVID Antibody Detection Kit 'DIPCOVAN', To Be Launched Early Next Month
Covid-19 antibody detection kit DIPCOVAN (PIB)
Defence Institute of Physiology and Allied Sciences (DIPAS), a laboratory of Defence Research and Development Organisation (DRDO), has developed an antibody detection-based kit 'DIPCOVAN'.
The DIPCOVAN kit can detect both spike as well as nucleocapsid (S&N) proteins of SARS-CoV-2 virus with a high sensitivity of 97 per cent and specificity of 99 per cent. The kit has been developed in association with Vanguard Diagnostics Pvt Ltd, a development and manufacturing diagnostics company based at New Delhi.
The DIPCOVAN kit was developed indigenously by the scientists, followed by extensive validation on more than 1,000 patient samples at various Covid designated hospitals in Delhi.